Oss, November, 13th, 2017 – Pivot Park organizes the symposium Breakthroughs in Precision Cancer Treatment on Tuesday November 21st. As part of the conference, NTRC has organized one of the scientific sessions, entitled ‘Drug discovery: from target to preclinical candidate’. In the session, scientists from NTRC and Lead Pharma will present different aspects of the discovery and development of new precision drug candidates for cancer. The challenges of the different phases of small molecule drug discovery will be described based on real case stories from the drug discovery programs of the two companies.
Program session ‘Drug discovery: from target to preclinical candidate’:
1.35 Hit identification and optimization (Lead Pharma)
2.10 Lead optimization and structure-based drug design (NTRC)
2.30 Patient stratification strategies (NTRC)
3.00 End of session
NTRC will also exhibit at the symposium.
NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services (Oncolines™, OncolinesProfiler™, GeneNominator™, SynergyFinder™ and SynergyScreen™) and target residence time measurements for protein kinases (ResidenceTimer™) on a fee-for-service basis. NFK GreenScreen™, an assay read-out for the cancer immunotherapy drug targets IDO1 and TDO, is supplied to clients globally. NTRC has internal drug discovery programs on TTK, IDO1 and TDO. For more information please visit www.ntrc.nl or contact email@example.com